Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Roivant Sciences (ROIV) Gains from Sales and Divestitures (2022 - 2025)

Roivant Sciences (ROIV) has disclosed Gains from Sales and Divestitures for 4 consecutive years, with $297795.0 as the latest value for Q2 2025.

  • For the quarter ending Q2 2025, Gains from Sales and Divestitures rose 2.35% year-over-year to $297795.0, compared with a TTM value of $297795.0 through Jun 2025, up 2.35%, and an annual FY2025 reading of $1.2 million, down 4.91% over the prior year.
  • Gains from Sales and Divestitures was $297795.0 for Q2 2025 at Roivant Sciences, down from $1.2 million in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $6.9 million in Q1 2023 and bottomed at $290968.0 in Q2 2024.
  • Average Gains from Sales and Divestitures over 4 years is $2.2 million, with a median of $1.2 million recorded in 2024.
  • The sharpest move saw Gains from Sales and Divestitures soared 139.46% in 2023, then plummeted 87.74% in 2024.
  • Year by year, Gains from Sales and Divestitures stood at $2.3 million in 2022, then skyrocketed by 139.46% to $5.5 million in 2023, then decreased by 10.21% to $4.9 million in 2024, then crashed by 93.97% to $297795.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for ROIV at $297795.0 in Q2 2025, $1.2 million in Q1 2025, and $4.9 million in Q4 2024.